New Research from Caris Life Sciences Finds Immunotherapy Resistance in Leiomyosarcoma

IRVING, Texas: IRVING, Texas, June 4, 2021 /PRNewswire/ -- Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, to present findings that provide a deeper understanding of how immunotherapies (IO) affect leiomyosarcoma (LMS), a rare cancer that affects smooth...

Click to view original post